Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study-Reference-Cited by-同舟云学术

Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study

Published:2022-01-18 Issue:1 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Vavro Cindy¹^ORCID,Ruel Theodore²,Wiznia Andrew³,Montañez Nicole⁴,Nangle Keith⁵,Horton Joseph⁵,Buchanan Ann M.¹,Stewart Eugene L.⁶,Palumbo Paul⁷

Affiliation:

1. ViiV Healthcare, Research Triangle Park, North Carolina, USA

2. University of California San Francisco, San Francisco, California, USA

3. Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA

4. FHI 360, Durham, North Carolina, USA

5. Parexel International, Durham, North Carolina, USA

6. GlaxoSmithKline, Upper Providence, Pennsylvania, USA

7. Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, USA

Abstract

P1093 is a multicenter, open-label, phase I/II study of pharmacokinetics, safety, and tolerability of dolutegravir plus an optimized background regimen in pediatric participants aged 4 weeks to <18 years with HIV-1. Most participants were highly treatment experienced.

Funder

ViiV Healthcare

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01645-21

Reference36 articles.

1. HHS Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV. Guidelines for the use of antiretroviral agents in pediatric HIV infection. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/PedARV_GL.pdf. Accessed 20 September 2020.

2. Barriers to Medication Adherence in HIV-Infected Children and Youth Based on Self- and Caregiver Report

3. Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trial

4. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

5. Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and Optimization of Oligonucleotide Ligation Assay (OLA) Probes for Detection of HIV-1 Resistance to Dolutegravir;Viruses;2024-07-19

2. Paediatric antiretroviral therapy challenges with emerging integrase resistance;Current Opinion in HIV and AIDS;2024-07-05

3. Virologic outcomes with tenofovir-lamivudine-dolutegravir in adults failing PI-based second-line ART;Southern African Journal of HIV Medicine;2024-04-26

4. Prevalence of Emergent Dolutegravir Resistance Mutations in People Living with HIV: A Rapid Scoping Review;Viruses;2024-03-04

5. Impact of Genetic Variants in ABCG2, NR1I2, and UGT1A1 on the Pharmacokinetics of Dolutegravir in Children;JAIDS Journal of Acquired Immune Deficiency Syndromes;2024-03-01